Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2025, titled "CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia? and Xgeva?".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09, 2025, titled "CuraTeQ Biologics completes a successful Phase 1 Pharmacokinetics study of Denosumab BP16, a proposed biosimilar to Prolia? and Xgeva?".